Principal Financial Group Inc. Lowers Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Principal Financial Group Inc. cut its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 11.9% during the third quarter, HoldingsChannel.com reports. The fund owned 229,089 shares of the company’s stock after selling 31,062 shares during the quarter. Principal Financial Group Inc.’s holdings in Omnicell were worth $9,988,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Arizona State Retirement System increased its holdings in Omnicell by 2.9% during the 2nd quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock worth $348,000 after purchasing an additional 357 shares during the period. Diversified Trust Co increased its stake in shares of Omnicell by 3.3% during the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock valued at $416,000 after buying an additional 494 shares during the period. GAMMA Investing LLC increased its stake in shares of Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after buying an additional 553 shares during the period. Louisiana State Employees Retirement System lifted its stake in Omnicell by 2.7% in the second quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock worth $625,000 after acquiring an additional 600 shares during the period. Finally, ProShare Advisors LLC grew its holdings in Omnicell by 7.4% during the 1st quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock worth $265,000 after acquiring an additional 626 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Omnicell Trading Up 0.8 %

Shares of OMCL opened at $46.05 on Tuesday. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.74. The firm has a market cap of $2.13 billion, a P/E ratio of -117.10, a price-to-earnings-growth ratio of 43.97 and a beta of 0.81. The company’s 50-day moving average price is $44.20 and its 200 day moving average price is $36.96.

Analysts Set New Price Targets

OMCL has been the topic of a number of recent research reports. Wells Fargo & Company increased their price objective on shares of Omnicell from $30.00 to $41.00 and gave the company an “equal weight” rating in a research note on Monday, October 14th. Craig Hallum increased their target price on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research report on Friday. Barclays raised their price objective on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, Benchmark reissued a “buy” rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, Omnicell presently has an average rating of “Hold” and a consensus price target of $50.83.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.